Who was studied, and how
Four numbers in the abstract
Where each one falls
Only readable comparisons vote
Where it lands on the map
What it changes
Among 8 other studies
1,050people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
1,800 mg of EPA + statin
statin alone
Reduced major coronary events−23%
randomisedAmong patients with prior myocardial infarction (MI), the trial randomly assignedassigned by chance
1,800 mg of EPA + statin
statin alone
May have reduced major coronary events−27%
randomised · one subgroupthe abstract, start to end
… (8.7% vs 10.7%, adjusted hazard ratio =0.77, 95% confidence interval (CI) 0.63-0.96, P=0.017, number needed to treat (NNT) =49).
… group (20.1%, adjusted hazard ratio =0.73, 95%CI 0.54-0.98, P=0.033, NNT =19).
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Major coronary events (MCE)1,800 mg of EPA + statin vs statin alone
HR 0.770.63–0.96
Major coronary events (MCE)1,800 mg of EPA + statin vs statin alone
NNT 49
Major coronary events (MCE)1,800 mg of EPA + statin vs statin alone, in patients with prior myocardial infarction (MI)
HR 0.730.54–0.98
Major coronary events (MCE)1,800 mg of EPA + statin vs statin alone, in patients with prior myocardial infarction (MI)
NNT 19
StatinsOther lipid agentsCardiovascular events
Other lipid agents × cardiovascular eventshelps?settled
unlikelylikely
0.800.50 without it
Statins × cardiovascular eventshelps?replicated
unlikelylikely
0.860.85 without it
← favours treatmentfavours comparator →
1 / 7